 To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer NSCLC that is confirmed to be positive for a ROS1 positive gene mutation translocation or inversion and confirmed negative for an ALK mutation 